首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer science

缩写:CANCER SCI

ISSN:1347-9032

e-ISSN:1349-7006

IF/分区:4.9/Q2

文章目录 更多期刊信息

共收录本刊相关文章索引6291条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Junlin Gan,Xuesong Bai,Aijie Zhang et al. Junlin Gan et al.
Tripartite motif-containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood. In this study, we identified TRIM59 as a clinically relevant oncog...
Ryuji Okamoto,Yukai Lu,Taisuke Ishii et al. Ryuji Okamoto et al.
Historically, information on routes of diagnosis in cancer registration in Japan lacked reliability. The launch of the National Cancer Registry in 2016 produced a marked improvement in data accuracy. In this study, we aimed to estimate the ...
Le Wang,Yu Qiu,Xuechen Chen et al. Le Wang et al.
Implementation of a RAP-based risk-adapted screening strategy enables personalized screening initiation, with benefits comparable to those observed in the current 50-54-year age group. ...
Hiroyuki Hagiwara,Hideyuki Takahashi,Reika Kawabata-Iwakawa et al. Hiroyuki Hagiwara et al.
Lymph node (LN) metastasis is one of the major prognostic factors in head and neck squamous cell carcinoma (HNSCC), and treatment sensitivity often differs between primary tumors and metastatic LNs. Beyond tumor cell-intrinsic differences, ...
Fenge Li,Xuejiao Ma,Yongming Xue et al. Fenge Li et al.
Tumor-infiltrating lymphocytes (TIL) therapy has demonstrated clinical potential in malignancies. However, limited understanding of why only a subset of patients respond to TIL therapy, coupled with the lack of simple and efficient methods ...
Ken-Ichi Yoshioka,Yusuke Matsuno,Rika Kusumoto-Matsuo Ken-Ichi Yoshioka
Cancer frequently develops in association with genomic instability, which includes massive induction of chromosomal structural variants (SVs) and single nucleotide variants (SNVs). SVs are typically caused by erroneous repair of DNA double-...
Sihong Le,Yitao Le,Xianshen Sha et al. Sihong Le et al.
Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to therapeutic resistance and tumor progression. Mitochondrial ribosomal proteins (MRPs), particularly MRPS23, have recently emerged as critical regula...
Akihiro Yoshimura,Juichiro Yoshida,Chieko Takumi et al. Akihiro Yoshimura et al.
HER2-mutant non-small cell lung cancer (NSCLC) comprises molecularly heterogeneous tumors with diverse ERBB2 mutation subtypes, and HER2-directed therapies have increased the need for refined molecular stratification. However, subtype-speci...
Yuichiro Semba,Toshihiro Miyamoto,Senji Kasahara et al. Yuichiro Semba et al.
Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy an...
Yuichiro Semba,Toshihiro Miyamoto,Senji Kasahara et al. Yuichiro Semba et al.
Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy an...